Cholesterol chelator, HPβCD for renal diseases
There is increasing evidence that accumulation of intracellular lipids in the kidney contributes to the pathogenesis and progression of kidney
Tag: Cholesterol
Treatment of Niemann-Pick Disease Type C using crosslinked 2-hydroxypropyl-β-cyclodextrin
Niemann-Pick Disease Type C (NPC) is a severe neurovisceral disorder that is pathophysiologically characterized by intracellular transport abnormalities leading to
CD-related papers in Scientific Reports
Scientific reports (Nature) has published 10 cyclodextrin-related papers in the last 3 months. Here is a selection: Parvez, S., Yadagiri,
Use of cyclodextrin or its complexes as a potential treatment against the 2019 novel coronavirus
Coronavirus 2 is a member of a virus family with lipid envelope that fuses with host cell through endocytosis, internalizing
Coronavirus Interplay With Lipid Rafts and Autophagy Unveils Promising Therapeutic Targets.
The plasma membrane microdomain lipid rafts have been found by researchers to be involved in the replication cycle of numerous
Cyclodextrin-impregnated masks to prevent the transmission of coronavirus
CycloLab’s submission to InnoCentive Challenge 9934291 – New Technologies to Prevent the Transmission of Coronavirus led to a favorable evaluation.
Potential COVID-19 therapeutics from a rare disease: utilization of lipid dysregulation to combat viral infectivity
Strategic drug repurposing in combination with rapid testing of established molecular targets could provide a pause in disease progression and
The Lord of the NanoRings: cyclodextrins and the battle against SARSCoV-2
Making a comparison between CDs and the unique Ring of the legendary novel of The Lord of the Rings, J.
Ototoxicity of cyclodextrin derivatives
There are two possible mechanisms behind the ototoxicity of 2-hydroxypropyl-β-cyclodextrin (HPBCD) treatment. One is : the possible interaction of HPBCD
Cyclodextrin dimers to treat atherosclerotic plaques by targeting various forms of cholesterol
SENS Research Foundation (USA, California) filed a PCT patent application (WO2020142716) that was recently published. In the invention, a new class